We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EVOLVING FDA INSPECTION PROCESS WILL PLACE GREATER PRESSURE ON MANAGERS, OFFICIAL SAYS

EVOLVING FDA INSPECTION PROCESS WILL PLACE GREATER PRESSURE ON MANAGERS, OFFICIAL SAYS

June 26, 2006

Managers at device and diagnostics manufacturing facilities can expect to bear the brunt of accountability for lapses in their quality systems (QS), a compliance official with the FDA's Center for Devices and Radiological Health (CDRH) said at a recent industry conference.

In conducting inspections, "There is going to be some new scrutiny, particularly on management," Casper Uldriks, special assistant to the director of compliance at CDRH, said June 20 at the Medical Device and Diagnostics Marketing Compliance Congress in Washington, D.C.

As part of an emerging new approach, the agency is planning to ramp up its review of companies' management systems. It's not just what managers say they're going to do -- it's what they do that matters, said Uldriks. "We want results."

"If people aren't making the right decisions or aren't making decisions at all," it can have a negative ripple effect on the whole system, he noted.

To enhance its oversight of management processes, CDRH is placing "a new focus on the entire corporation" that will include multisite inspections affecting both premarket and postmarket devices, as well as exports and imports, Uldriks noted.

Uldriks wondered aloud whether executives and managers are often out of the loop in terms of responding to adverse events and other lapses in the QS. Executives and managers need to work together, Uldriks said. "If they are isolated from each other, [the QS] won't work."

(http://www.fdanews.com/ddl/33_26/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • abbott-logo.gif

    Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

  • 100Bills_flatmoney.gif

    In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing